Dublin, Dec. 19, 2016 -- Research and Markets has announced the addition of Jain PharmaBiotech's new report "Cardiovascular Drug Delivery - Technologies, Markets and Companies" to their offering.
The cardiovascular drug delivery markets are estimated for the years 2015 to 2025 on the basis of epidemiology and total markets for cardiovascular therapeutics.
The estimates take into consideration the anticipated advances and availability of various technologies, particularly drug delivery devices in the future. Markets for drug-eluting stents are calculated separately. Role of drug delivery in developing cardiovascular markets is defined and unmet needs in cardiovascular drug delivery technologies are identified.
Role of drug delivery in various cardiovascular disorders such as myocardial ischemia, hypertension and hypercholesterolemia is discussed. Cardioprotection is also discussed. Some of the preparations and technologies are also applicable to peripheral arterial diseases. Controlled release systems are based on chronopharmacology, which deals with the effects of circadian biological rhythms on drug actions.A full chapter is devoted to drug-eluting stents as treatment for restenosis following stenting of coronary arteries.Fifteen companies are involved in drug-eluting stents.
Selected 82 companies that either develop technologies for drug delivery to the cardiovascular system or products using these technologies are profiled and 80 collaborations between companies are tabulated. The bibliography includes 200 selected references from recent literature on this topic. The report is supplemented with 30 tables and 8 figures.
Key Topics Covered:
Executive Summary
1. Cardiovascular Diseases
2. Methods for Drug Delivery to the Cardiovascular System
3. Cell Therapy for Cardiovascular Disorders
4. Gene Therapy for Cardiovascular Disorders
5. Drug-Eluting Stents
6. Markets for Cardiovascular Drug Delivery
7. Companies involved in Cardiovascular Drug Delivery
8. References
For more information about this report visit http://www.researchandmarkets.com/research/8vqw45/cardiovascular
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Drug Delivery


Apple Turns 50: From Garage Startup to AI Crossroads
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
First Western Ship Transits Strait of Hormuz Since Iran War Began 



